perphenazine has been researched along with fluvoxamine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Reznik, I; Sirota, P | 1 |
| Abramovitchi, I; Bloch, Y; Diskin, A; Kaplan, D; Levkovitz, Y | 1 |
| Baumann, P; Eap, CB; Zullino, DF | 1 |
1 review(s) available for perphenazine and fluvoxamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for perphenazine and fluvoxamine
| Article | Year |
|---|---|
Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Compulsive Behavior; Female; Fluvoxamine; Haloperidol; Humans; Male; Middle Aged; Obsessive Behavior; Perphenazine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 2000 |
Fluvoxamine for psychosis in Alzheimer's disease.
Topics: Acute Disease; Aged; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Brief Psychiatric Rating Scale; Cross-Over Studies; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Male; Perphenazine; Pilot Projects; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
5 other study(ies) available for perphenazine and fluvoxamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluvoxamine; Humans; Perphenazine; Psychiatric Status Rating Scales; Psychotic Disorders; Treatment Outcome | 2001 |